SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now ...

It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal ...

Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Drug therapy: Currently, anti-VEGFs are the go-to choice for treating DME. Recently, newer intravitreal agents targeting VEGF ...

Currently 4.4 million people in the UK who live with diabetes are at a higher risk of developing eye diseases and vision loss ...

Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that ...

Depending on the stage of Retinopathy, multiple treatment modalities are available. Very early changes need only better glycaemic control and frequent monitoring with fundus examination. For managing ...